A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin a Conjugated Anti-CD22 Monoclonal Antibody to Frontline Therapy in Young Adults Ages 18-39 Years with Newly Diagnosed Precursor B-Cell ALL

Brief Summary

Type:
Leukemias

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT03150693

Study #:
STUDY00143245

Start Date:
Mar 05, 2019

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03150693

View Complete Trial Details & Eligibility at ClinicalTrials.gov